AstraZeneca’s Alexion $39bn takeover

Introduction: On 12 December 2020, AstraZeneca announced a definitive agreement to acquire Alexion Pharmaceuticals, for a value of $39 bn. For each share of Alexion, the shareholders will receive $60 in cash and a little over 2 AstraZeneca American Depositary Shares (ADS), corresponding to half of an ordinary AstraZeneca share. Alexion shareholders will own a 15% share in … Continue reading AstraZeneca’s Alexion $39bn takeover

Bristol Myers Squibb acquires MyoKardia, expanding its cardiovascular portfolio

Introduction: On October 5th, Bristol Myers Squibb announced a definitive agreement to acquire MyoKardia for $225 per share, totaling the deal value to approximately $13.1bn in cash. The transaction was unanimously approved by the Boards of Directors of both companies and was successfully completed on November 17th. With the completion of the acquisition, MyoKardia was … Continue reading Bristol Myers Squibb acquires MyoKardia, expanding its cardiovascular portfolio

Siemens Healthineers’ acquisition of Varian Medical Systems for $16.4bn

Introduction:  On August 2nd, Siemens Healthineers announced a definitive agreement to acquire all shares of Varian Medical Systems for $177.5 per share, which corresponds to a purchase price of approximately $16.4bn in cash. This transaction builds on the long-standing collaboration between Siemens Healthineers and Varian to develop improved cancer therapy solutions. Since 2012, they have been working together successfully … Continue reading Siemens Healthineers’ acquisition of Varian Medical Systems for $16.4bn

Johnson & Johnson paves its way into Robotic Surgery field

On February 13th, Johnson & Johnson announced it entered in a definitive agreement to acquire Silicon Valley surgical robotics company Auris Health for $3.4 billion in cash. The deal is considered to be one of the 10 largest venture-backed private deals and highlights J&J's efforts to become a global leader in surgical robotics. Companies Overview … Continue reading Johnson & Johnson paves its way into Robotic Surgery field

Elliott and Veritas acquire Athenahealth in a $5.7 billion deal

Companies overview Elliott Management Elliott Management Corporation is an activist hedge fund and manages two multi-strategy investment funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds' investors … Continue reading Elliott and Veritas acquire Athenahealth in a $5.7 billion deal

CVS Acquires Aetna in the Largest American Healthcare Insurance Deal of All Time

On December 3rd, 2017 CVS Health Corporation announced its intention to acquire Aetna Inc. in a cash-stock deal for $69 billion, in what will be the largest corporate deal in 2017 so far. The Wall Street Journal reported that the two companies have been in talks since late October. CVS’ stock dropped more than 4.6% … Continue reading CVS Acquires Aetna in the Largest American Healthcare Insurance Deal of All Time

American Beauty: The Healthcare Puzzle

“The Constitution imposes no obligation on the States ... to pay any of the medical expenses of indigents” US Supreme Court, 1977 The US is the only industrialized nation with selective healthcare coverage, meaning that basic healthcare services are not provided to everybody and paid for by the government (or government-managed entities), and this has … Continue reading American Beauty: The Healthcare Puzzle

Bayer-Monsanto: A Genetically Modified Deal

On September 14th, 2016, Bayer has reached a deal, currently pending regulatory approval, to acquire Monsanto in an all cash transaction for $128-a-share ($56bn Equity Value, $66bn EV) COMPANY OVERVIEW – BAYER Bayer AG (ETR:BAYN , Market Cap: €77.57bn, Share Price: €93.90 as of 11/11/2016) is a German multinational chemical and pharmaceutical company traded on the Frankfurt Stock Exchange. … Continue reading Bayer-Monsanto: A Genetically Modified Deal

ChemChina still in the run for its global primacy, this time is the agrochemical giant Syngenta to fall in its arms

On February 3rd, 2016 ChemChina announced its acquisition of Syngenta’s 100% outstanding share capital at $465 per ordinary share and a special dividend of CHF 5 to be paid only conditionally on the closing of the transaction. The deal comes after several failed acquisition attempts by Monsanto towards Syngenta, declined due to a reportedly too … Continue reading ChemChina still in the run for its global primacy, this time is the agrochemical giant Syngenta to fall in its arms